Non-Small Cell Lung Cancer- Localized and Unresectable

Correlatives
No Trials Currently Available

Inoperable Stage I/II
- IRB#20077 A Phase II Randomized Study of Ramucirumab plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
- IRB#19566 A PHASE II STUDY OF RUCAPARIB IN PATIENTS WITH GENOMIC LOH HIGH AND/OR DELETERIOUS BRCA1/2 MUTATION STAGE IV OR RECURRENT NSCLC (LUNG-MAP SUB-STUDY)

Inoperable Stage IIA/B
- IRB#20077 A Phase II Randomized Study of Ramucirumab plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
- IRB#19566 A PHASE II STUDY OF RUCAPARIB IN PATIENTS WITH GENOMIC LOH HIGH AND/OR DELETERIOUS BRCA1/2 MUTATION STAGE IV OR RECURRENT NSCLC (LUNG-MAP SUB-STUDY)

CROSS-DISEASE TRIALS:
- IRB# 19992 EAY131 (MATCH)
- IRB# TBD S1609 (DART)

Key:
- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php